AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05514132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.
Study NCT05514132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.
Study NCT05247840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular autonomic dysfunction test proposed by Ewing et al.
Description: CAD will be assessed by five reproducible and standardized cardiovascular reflex tests described by Ewing et al. Three of the five tests assess parasympathetic function: heart rate response to deep breathing, to standing, and the Valsalva maneuver. Two tests evaluate sympathetic function which are blood pressure responses from lying to standing and at sustained handgrip. Each of these five tests is assigned a score of 0 for normal, 0.5 for borderline, and 1 for abnormal results. The sum of these 5 scores - which is the Ewing score - is used to assess severity of CAD. Patients having Ewing score ≥ 2 form the CAD + group, and patients who have less than 2 form the CAD - group.
Study NCT05738148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin group Vasopressin will be via umbilical vein catheter (0.4 IU/kg per dose - first line) or alternatively via an endotracheal tube (8 IU/kg) every three to five minutes as needed with a maximum of two doses if there is no ROSC \[2,3\] After that, the clinical team must convert to give epinephrine (0.02 mg/kg per dose) as long as CPR is ongoing.
Study NCT05247840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: peripheral nerve conduction test
Description: Peripheral neuropathy will be evaluated by nerve conduction test. The device measures motor conduction in the lower extremities. It operates at two dedicated frequencies in order to perform a thick myelin sheath cordless fibre (5Hz) and thin myelinated nerve fibre (2000Hz) examination. The device will be calibrated according to the prescribed instructions for use by a skilled technician.
Study NCT05835024 — intervention group
Intervention type: DEVICE
Intervention: Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 1
Description: A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.~A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation.
Study NCT05835024 — intervention group
Intervention type: DEVICE
Intervention: Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 2
Description: A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.
Study NCT05738148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine group Epinephrine will be administered according to current resuscitation guidelines either via umbilical vein catheter (0.02 mg/kg per dose) or via endotracheal tube (0.1 mg/kg) every three to five minutes as needed\[2,3\]. Chest compressions and epinephrine will be continued until ROSC.
Study NCT05375643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SURGE
Description: Video with or without person to person guidance to support decision making around genetic testing
Study NCT05377008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMAL-SSI
Description: The purpose of the intervention feedback session will be twofold: 1) to provide the results of the previous assessment, and 2) to provide general psychoeducation on psychological and neurocognitive functioning and tailored cognitive and behavioral interventions based on the results in order to reduce the impact of psychological and neurocognitive deficits.
Study NCT05399303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturation
Description: obturation using different types of sealers
Study NCT06429618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Low carbonhydrate diet
Description: Each patient will receive a 3-month low-carbohydrate (40% CHO) diet from the same dietitian. Whether the patients adhere to the diet and which components the prescribed diet consists of is recorded in detail. After 3 months of standard application, the patient is examined again by the gynecologist and obstetrician at the PCOS clinic.
Study NCT06391177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Oral tablet.
Study NCT05515094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment Counseling Intervention
Description: The intervention entails case managers conducting first-line support (i.e., a brief psychosocial support session), and a safety and health assessment, adapted from current case management content and the Safe and Sound intervention.
Study NCT06279429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sideral® Sucrosomial Iron
Description: Sucrosomial Iron 30mg
Study NCT06279429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron chewable tablet
Description: Iron chewable tablet 100mg
Study NCT04187950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt with B. lactis and added honey
Description: The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with honey twice daily for 14 days.
Study NCT04187950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt with heat-inactivated B. lactis and added cane sugar
Description: The control condition will utilize a commercially available yogurt (Activia) following heat inactivation of the probiotic Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of the heat-inactivated yogurt with added cane sugar twice daily for 14 days.The added cane sugar will be an isocaloric amount to the honey.
Study NCT06289140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pterostilbene cocrystal (ccPT) - Gelatin capsule
Description: Participants will intake one gelatin capsule with 75 mg of Pterostilbene cocrystal (ccPT).
Study NCT06518499 — intervention group
Intervention type: PROCEDURE
Intervention: Pilonidal sinus surgery
Description: Bascom's Pit-Pick procedure, Primary Closure, Karydakis procedure
Study NCT05974826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the SI! Program for Secondary Schools (NCT03504059)
Description: The SI! Program is implemented from 1st to 4th grade of Secondary Schools. A total of 12 hours of classroom intervention per academic year, organized through three educational units, and with active and participative methodologies, and complementary intervention in the family setting, at school and on teachers.
Study NCT05974826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Fifty-Fifty Program (NCT02367963)
Description: 1. Training stage: the focus is on improving individual health, through workshops (given in person by experts), and on the challenges of changing habits supervised and supported by the SHE Foundation~2. Peer-to-peer support group sessions: It is designed to make the subjects participate actively in their healthcare. Along the sessions subjects propose assumable health goals. Participants will be able to view videos with key messages from the workshops to continue the sustainability of the changes made, and the development of new ones. Peer-to-peer support group sessions have two phases: a) leaders will receive support from the Foundation; b) participants will become agents of change with the people around them, and also in their municipality with specific actions to promote health. The role of Foundation's will only be to monitor and resolve possible doubts.
Study NCT04950751 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: candidate vaccine, SCB-2020S
Description: a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
Study NCT04950751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: candidate vaccine, SCB-2020S
Description: a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
Study NCT05604586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 women and men supplementing 1200 mg of placebo daily in three equal doses. Supplementation will last for 7 days.
Study NCT06022809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dada Kwa Dada (individual-level)
Description: Dada Kwa Dada (DKD) intervention is an adapted version of Sister to Sister (S2S) intervention (a brief, health profession-led, individual-level intervention proven to increase condom use and decrease STIs among African American women). Intervention is a 1hr to 1.5hrs session and offered in English or French.
Study NCT06022809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DADA (group-level)
Description: DADA intervention is an adapted version of Sisters Informing Sisters about Topics on AIDS (SISTA) intervention (a peer-led, group-level intervention proven to increase condom use and decrease STIs among African American women). This is a 6hrs intervention implemented in two three-hour sessions and offered in English or French.
Study NCT05986487 — intervention group
Intervention type: DEVICE
Intervention: CPAP or usual practice
Description: CPAP (continuous positive airway pressure) is a machine that uses mild air pressure to keep breathing airways open while you sleep.
Study NCT05986487 — intervention group
Intervention type: DEVICE
Intervention: Monitoring and intervention in follow-up
Description: Each participating center can incorporate monitoring and intervention in the follow-up of patients into their work dynamics. Through the use of mobile applications, you can monitor the variables of: weight, diet, lifestyle, exercise and sleep. This intervention will help the patient to improve in different aspects of their health.
Study NCT06365502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed.
Study NCT06365502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical treatment
Description: All individuals will receive guideline-directed medical treatment.
Study NCT06365502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-directed medical treatment
Description: All individuals will receive guideline-directed medical treatment.
Study NCT05307289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biposy
Description: Biopsy at inclusion visit and at disease progression if applicable
Study NCT05185882 — intervention group
Intervention type: OTHER
Intervention: Single leg squat
Description: Single leg squat exercise in different circumstances
Study NCT04711252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Dosage formulation: AZD9833 tablets will be administered orally
Study NCT04711252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Dosage formulation: Anastrozole tablets will be administered orally.
Study NCT04711252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole placebo
Description: Dosage formulation: anastrozole placebo tablets will be administrated orally.
Study NCT04711252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD9833 placebo
Description: Dosage formulation: AZD9833 placebo tablets will be administrated orally.
Study NCT04711252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dosage formulation: palbociclib tablets/capsules will be administered orally
Study NCT05558267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Table Salt
Description: Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.
Study NCT05558267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt Substitute
Description: Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt.~Salt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.
Study NCT05338320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Erector Spinae Plane Block
Description: General anesthesia and Ultrasound Guided Erector Spinae Plane Block
Study NCT05338320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: General anesthesia and intrathecal morphine
Study NCT05338320 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: General anesthesia using intravenous fentanyl (1µg/kg)
Description: General anesthesia using intravenous fentanyl (1µg/kg)
Study NCT06433921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-152a
Description: A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
Study NCT06289140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pterostilbene free form (PT)
Description: Participants will intake one capsule with 50 mg of Pterostilbene free form (PT)
Study NCT06289140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pterostilbene cocrystal (ccPT) - Gastro-resistant capsule
Description: Participants will intake one gastro-resistant capsule with 75 mg of Pterostilbene cocrystal (ccPT).
Study NCT06411145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXERVATE® 0.002%
Description: Cenegermin-bkbj (20 mcg/mL) is an ophthalmic solution contained in a multiple-dose vial. The topical drops are administered 6 times/day for a 8-week course.
Study NCT06197672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4CAR
Description: CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
Study NCT04746859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention Visit
Description: Patients will have a one-on-one, approximately one-hour long visit with a specially trained Prevention Practitioner. During this visit, they will discuss the patient's health history, their risks for developing chronic diseases, including cancer, and possible steps they can take to reduce those risks. The Prevention Practitioner will also assist the patient to develop and articulate specific goals the patient would like to work on to reduce their risk of chronic diseases.
Study NCT04746859 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prevention Visit
Description: Patients will have a one-on-one, approximately one-hour long visit with a specially trained Prevention Practitioner. During this visit, they will discuss the patient's health history, their risks for developing chronic diseases, including cancer, and possible steps they can take to reduce those risks. The Prevention Practitioner will also assist the patient to develop and articulate specific goals the patient would like to work on to reduce their risk of chronic diseases.
Study NCT04746859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer health coaching
Description: Patients will be invited to register with the software platform used to facilitate peer health coaching. Once they have registered, they will be matched to a peer health coach who will connect with the patient to initiate the process. The coach will work collaboratively with the patient to help her follow through on a step-wise, personalized plan to achieve health goals that were developed with their prevention practitioner. The coach's approach will be informed by principles of brief action planning and motivational interviewing. Coaches will also provide social support, help to navigate to relevant information and community resources, and advise about options for self-monitoring. Coaching will occur over 12-16 sessions via phone calls, text messages, video calls and/or in-person meetings as desired/convenient and in accordance with local public health guidelines.
Study NCT05349877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.
Study NCT05349877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Description: Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.
Study NCT05349877 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.
Study NCT04711252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Dosage formulation: palbociclib tablets/capsules will be administered orally
Study NCT04711252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonist
Description: Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Study NCT04711252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonist
Description: Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Study NCT06550024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SakuraBead Resorbable Microspheres
Description: Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres
Study NCT06550024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Corticosteroid injection in the knee
Study NCT06305104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5μg/ml EEC
Description: 0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients
Study NCT06433921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-134a
Description: A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
Study NCT06433921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.
Study NCT06305104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml EEC
Description: 0.1ml, one time, containing high dose 5μg/ml of active ingredients
Study NCT05382533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Menu plans
Description: The study participants in group A and C receive defined personal nutritional counselling every two weeks and they are provided with daily menu plans (isocaloric) with optimized nutrient profiles and chosen study products (plant oils, nuts mixture etc.) over the study period of 10 weeks.
Study NCT06507644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: light curettage
Description: Before the treatment, the treated area will be degreased with 0.2% aqueous chlorhexidine. Next, a light curettage will be performed on the face with a sterile curette.
Study NCT06507644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: light curettage
Description: Before the treatment, the treated area will be degreased with 0.2% aqueous chlorhexidine. Next, a light curettage will be performed on the face with a sterile curette.
Study NCT06507644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre irradiation of 1 hour
Description: A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 1 hour.
Study NCT06507644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre irradiation of 3 hour
Description: A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 3 hour.